TheStreet’s Jim Cramer says Celgene (CELG), which ended Friday’s session down more than 4-percent, is a great buy because the drugmaker is led by a great CEO. Cramer says Celgene CEO Robert Hugin has done a great job of diversifying the company’s drug portfolio. Shares of Celgene ended lower on word the UK would not immediately approve Celgene’s cancer drug, Revlemed, for reimbursement. Cramer believes the drug will eventually be approved for reimbursement everywhere.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
